(Q47439880)

http://europepmc.org/abstract/MED/29104284

16 January 2018

title

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases (English)

1 reference

http://europepmc.org/abstract/MED/29104284

16 January 2018

author

Daniella M Schwartz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29104284%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Alejandro Villarino

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29104284%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Yuka Kanno

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29104284%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Michael Ward

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29104284%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Massimo Gadina

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29104284%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

John J O'Shea

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29104284%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

6 November 2017

1 reference

http://europepmc.org/abstract/MED/29104284

16 January 2018

published in

Nature Reviews Drug Discovery

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29104284%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29104284%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29104284%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

843-862

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29104284%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd.2017.201

7 June 2020

exact match

0 references

cites work

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

IL-6 biology: implications for clinical targeting in rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

C-reactive protein: a critical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Mepolizumab treatment in patients with severe eosinophilic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

JAKs and STATs in immunity, immunodeficiency, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The JAK-STAT pathway: impact on human disease and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8(+) T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Advances in kinase targeting: current clinical use and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Ibrutinib for the treatment of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Baricitinib in Patients with Refractory Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

IL-9 and its receptor are predominantly involved in the pathogenesis of UC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The IL-20 subfamily of cytokines--from host defence to tissue homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Revisiting Crohn's disease as a primary immunodeficiency of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib for the treatment of moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The role of lymphocytes in the development and treatment of alopecia areata

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib for the treatment of alopecia areata and variants in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Reversal of Alopecia Universalis by Tofacitinib: A Case Report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Efficacy of tofacitinib in treatment of alopecia universalis in two patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Transient Efficacy of Tofacitinib in Alopecia Areata Universalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Topical Ruxolitinib for the Treatment of Alopecia Universalis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Molecular mechanisms of pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Idiopathic erythema multiforme: Evidence of underlying Janus kinase-signal transducer and activator of transcription activation and successful treatment with tofacitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Regulatory immune cells in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

A case of refractory dermatomyositis responsive to tofacitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Remission of recalcitrant dermatomyositis treated with ruxolitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Long-term activation of the innate immune system in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Progressive multifocal leukoencephalopathy associated with ruxolitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The emerging safety profile of JAK inhibitors in rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Impact of tofacitinib treatment on human B-cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Origin and Function of Circulating Plasmablasts during Acute Viral Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Disease activity in rheumatoid arthritis and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Cardiovascular risk factor management in patients with RA compared to matched non-RA patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Interleukin-22: immunobiology and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Malignancy and Janus Kinase Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

FLT3 as a therapeutic target in AML: still challenging after all these years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Network pharmacology of JAK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Super-enhancers delineate disease-associated regulatory nodes in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

JAK-cytokine receptor recognition, unboxed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib for polyarteritis nodosa: a tailored therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib versus methotrexate in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Tofacitinib Response in Juvenile Idiopathic Arthritis (JIA) and Collagenous Colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

CYP3A genetics in drug metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.201

FDA approves tofacitinib for rheumatoid arthritis

31 March 2020

1 reference

12 December 2020

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

1 reference

12 December 2020

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis

1 reference

12 December 2020

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

1 reference

12 December 2020

Cytokines and chemokines in irritant contact dermatitis

1 reference

12 December 2020

The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)

1 reference

12 December 2020